Multi-ancestry polygenic risk scores for venous thromboembolism
Venous thromboembolism (VTE) is a significant contributor to morbidity and mortality, with large disparities in incidence rates between Black and White Americans. Polygenic risk scores (PRSs) limited to variants discovered in genome-wide association studies in European-ancestry samples can identify European-ancestry individuals at high risk of VTE. However, there is limited evidence on whether high-dimensional PRS constructed using more sophisticated methods and more diverse training data can enhance the predictive ability and their utility across diverse populations. We developed PRSs for VTE using summary statistics from the International Network against Venous Thrombosis (INVENT) consortium GWAS meta-analyses of European- (71,771 cases and 1,059,740 controls) and African-ancestry samples (7,482 cases and 129,975 controls). We used LDpred2 and PRSCSx to construct ancestry-specific and multi-ancestry PRSs and evaluated their performance in an independent European- (6,261 cases and 88,238 controls) and African-ancestry sample (1,385 cases and 12,569 controls). Multi-ancestry PRSs with weights tuned in European- and African-ancestry samples, respectively, outperformed ancestry-specific PRSs in European- (PRSCSXEUR: AUC=0.61 (0.60, 0.61), PRSCSX_combinedEUR: AUC=0.61 (0.60, 0.62)) and African-ancestry test samples (PRSCSXAFR: AUC=0.58 (0.57, 0.6), PRSCSX_combined AFR: AUC=0.59 (0.57, 0.60)). The highest fifth percentile of the best-performing PRS was associated with 1.9-fold and 1.68-fold increased risk for VTE among European- and African-ancestry subjects, respectively, relative to those in the middle stratum. These findings suggest that the multi-ancestry PRS may be used to identify individuals at highest risk for VTE and provide guidance for the most effective treatment strategy across diverse populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2024) vom: 10. Jan. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 02.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2024.01.09.24300914 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367507838 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367507838 | ||
| 003 | DE-627 | ||
| 005 | 20240202232156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240123s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.01.09.24300914 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM367507838 | ||
| 035 | |a (NLM)38260294 | ||
| 035 | |a (PII)2024.01.09.24300914 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jee, Yon Ho |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multi-ancestry polygenic risk scores for venous thromboembolism |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Venous thromboembolism (VTE) is a significant contributor to morbidity and mortality, with large disparities in incidence rates between Black and White Americans. Polygenic risk scores (PRSs) limited to variants discovered in genome-wide association studies in European-ancestry samples can identify European-ancestry individuals at high risk of VTE. However, there is limited evidence on whether high-dimensional PRS constructed using more sophisticated methods and more diverse training data can enhance the predictive ability and their utility across diverse populations. We developed PRSs for VTE using summary statistics from the International Network against Venous Thrombosis (INVENT) consortium GWAS meta-analyses of European- (71,771 cases and 1,059,740 controls) and African-ancestry samples (7,482 cases and 129,975 controls). We used LDpred2 and PRSCSx to construct ancestry-specific and multi-ancestry PRSs and evaluated their performance in an independent European- (6,261 cases and 88,238 controls) and African-ancestry sample (1,385 cases and 12,569 controls). Multi-ancestry PRSs with weights tuned in European- and African-ancestry samples, respectively, outperformed ancestry-specific PRSs in European- (PRSCSXEUR: AUC=0.61 (0.60, 0.61), PRSCSX_combinedEUR: AUC=0.61 (0.60, 0.62)) and African-ancestry test samples (PRSCSXAFR: AUC=0.58 (0.57, 0.6), PRSCSX_combined AFR: AUC=0.59 (0.57, 0.60)). The highest fifth percentile of the best-performing PRS was associated with 1.9-fold and 1.68-fold increased risk for VTE among European- and African-ancestry subjects, respectively, relative to those in the middle stratum. These findings suggest that the multi-ancestry PRS may be used to identify individuals at highest risk for VTE and provide guidance for the most effective treatment strategy across diverse populations | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Thibord, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Dominguez, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Sept, Corriene |e verfasserin |4 aut | |
| 700 | 1 | |a Boulier, Kristin |e verfasserin |4 aut | |
| 700 | 1 | |a Venkateswaran, Vidhya |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Cherlin, Tess |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Shefali Setia |e verfasserin |4 aut | |
| 700 | 1 | |a Faro, Valeria Lo |e verfasserin |4 aut | |
| 700 | 1 | |a Bartz, Traci M |e verfasserin |4 aut | |
| 700 | 1 | |a Boland, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Brody, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Deleuze, Jean-Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Emmerich, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Germain, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Andrew D |e verfasserin |4 aut | |
| 700 | 1 | |a Kooperberg, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Morange, Pierre-Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pankratz, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Psaty, Bruce M |e verfasserin |4 aut | |
| 700 | 1 | |a Reiner, Alexander P |e verfasserin |4 aut | |
| 700 | 1 | |a Smadja, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Sitlani, Colleen M |e verfasserin |4 aut | |
| 700 | 1 | |a Suchon, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Weihong |e verfasserin |4 aut | |
| 700 | 1 | |a Trégouët, David-Alexandre |e verfasserin |4 aut | |
| 700 | 1 | |a Zöllner, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Pasaniuc, Bogdan |e verfasserin |4 aut | |
| 700 | 1 | |a Damrauer, Scott M |e verfasserin |4 aut | |
| 700 | 1 | |a Sanna, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Snieder, Harold |e verfasserin |4 aut | |
| 700 | 0 | |a Lifelines Cohort Study |e verfasserin |4 aut | |
| 700 | 1 | |a Kabrhel, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Nicholas L |e verfasserin |4 aut | |
| 700 | 1 | |a Kraft, Peter |e verfasserin |4 aut | |
| 700 | 0 | |a INVENT Consortium |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2024) vom: 10. Jan. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:10 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.01.09.24300914 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 10 |c 01 | ||